Bone Biologics Current Ratio vs. Return On Asset
| BBLG Stock | USD 1.22 0.04 3.17% |
Current Ratio | First Reported 2010-12-31 | Previous Quarter 4.49573492 | Current Value 5.66 | Quarterly Volatility 23.09645201 |
For Bone Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bone Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bone Biologics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bone Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bone Biologics Corp over time as well as its relative position and ranking within its peers.
Bone |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.57) | Return On Equity (1.19) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Bone Biologics Corp Return On Asset vs. Current Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Bone Biologics's current stock value. Our valuation model uses many indicators to compare Bone Biologics value to that of its competitors to determine the firm's financial worth. Bone Biologics Corp is number one stock in current ratio category among its peers. It is rated below average in return on asset category among its peers . At this time, Bone Biologics' Current Ratio is most likely to increase significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Bone Biologics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Bone Return On Asset vs. Current Ratio
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Bone Biologics |
| = | 80.11 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Bone Biologics |
| = | -0.57 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Bone Return On Asset Comparison
Bone Biologics is currently under evaluation in return on asset category among its peers.
Bone Biologics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Bone Biologics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bone Biologics will eventually generate negative long term returns. The profitability progress is the general direction of Bone Biologics' change in net profit over the period of time. It can combine multiple indicators of Bone Biologics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -9.4 M | -9 M | |
| Income Before Tax | -8.9 M | -8.5 M | |
| Net Loss | -8.9 M | -8.5 M | |
| Total Other Income Expense Net | 479.6 K | 503.6 K | |
| Income Tax Expense | -2 M | -1.9 M | |
| Net Loss | -6.5 M | -6.8 M | |
| Net Loss | -1.9 M | -1.9 M | |
| Net Interest Income | -730.2 K | -766.7 K | |
| Interest Income | 1.9 K | 1 K | |
| Change To Netincome | 632.3 K | 600.7 K | |
| Net Loss | (34.01) | (35.71) | |
| Income Quality | 1.07 | 0.70 | |
| Net Loss | (0.54) | (0.51) |
Bone Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Bone Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bone Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bone Biologics' important profitability drivers and their relationship over time.
Use Bone Biologics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bone Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bone Biologics will appreciate offsetting losses from the drop in the long position's value.Bone Biologics Pair Trading
Bone Biologics Corp Pair Trading Analysis
The ability to find closely correlated positions to Bone Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bone Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bone Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bone Biologics Corp to buy it.
The correlation of Bone Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bone Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bone Biologics Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bone Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Bone Biologics position
In addition to having Bone Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Industrials ETFs Thematic Idea Now
Industrials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Industrials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
To fully project Bone Biologics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bone Biologics Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bone Biologics' income statement, its balance sheet, and the statement of cash flows.